Intellia Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $7,659 | $15,048 | $23,017 | $13,782 |
Gross Profit | 7,659 | 12,846 | 17,002 | -65,167 |
EBITDA | -104,534 | -94,029 | -95,409 | -96,388 |
EBIT | -106,634 | -96,231 | -95,786 | -101,324 |
Net Income | -106,634 | -96,231 | -95,786 | -101,324 |
Net Change In Cash | 7,659 | 15,048 | 23,017 | 13,782 |
Free Cash Flow | -202,347 | -117,425 | -69,411 | -76,928 |
Cash | 106,128 | 134,697 | 155,464 | 193,389 |
Basic Shares | 133,480 | 118,490 | 108,376 | 110,188 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $67,671 | $57,877 | $36,275 | $52,121 |
Gross Profit | 51,748 | 47,592 | 27,299 | 44,549 |
EBITDA | -396,771 | -508,736 | -472,216 | -466,614 |
EBIT | -412,694 | -519,021 | -481,192 | -474,186 |
Net Income | -412,694 | -519,021 | -481,192 | -474,186 |
Net Change In Cash | 67,671 | 57,877 | 36,275 | 52,121 |
Cost of Revenue | 409,977 | |||
Free Cash Flow | -354,658 | -354,658 | -408,071 | -391,677 |
Cash | 155,464 | 189,182 | 226,748 | 523,506 |
Basic Shares | 108,376 | 98,849 | 88,770 | 76,972 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.80 |
2026-03-31 | -$0.81 |
2025-12-31 | -$0.83 |
2025-09-30 | -$0.92 |